# A Study of Olaparib and Durvalumab in Prostate Cancer

> **NCT03810105** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03810105
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-07
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Due to low accrual
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03810105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03810105, "A Study of Olaparib and Durvalumab in Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03810105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*